A cross-sectional analysis of pharmaceutical industry-funded events for health professionals in Australia

BMJ Open 2017; 7: e016701.
Authors: Fabbri A, Grundy Q, Mintzes B, et al
“To analyse patterns and characteristics of pharmaceutical industry sponsorship of events for Australian health professionals and to understand the implications of recent changes in transparency provisions that no longer require reporting of payments for food and beverages.”
Find article here.

The case for an Indigenous Bioethics

Global Bioethics Blog, 25 June 2017
Author: Stuart Rennie
“Indigenous communities in the Americas experience a disproportionate incidence of illness and disease compared to the general population. They also possess sophisticated ethical traditions which diverge and not infrequently conflict with Western-oriented bioethics. This culture gap between patient, provider and ethicist is no small public health concern—it can foster feelings of alienation and distrust which compromise the relationship between those in need of care and those able to offer it. Research ethicists have already made considerable efforts to bring sensitivity for aboriginal cultural mores into their discipline, but bioethicists have been slower out of the gate.”
Find article here.

Pharmaceutical Marketing for Rare Diseases: Regulating Drug Company Promotion in an Era of Unprecedented Advertisement

JAMA. 2017; 317(24): 2479-2480.
Authors: Sham Mailankody, Vinay Prasad
“This Viewpoint uses the recent instance of disease awareness promotion on a television soap opera to discuss questions about the role and regulation of novel forms of direct-to-consumer disease awareness marketing.”
Find article here.

Indemnity provider calls for urgent reform of negligence payouts

BMJ 2017; 357: j3025
Author: Clare Dyer
“The spiralling cost of clinical negligence claims in England will become unsustainable unless the government reforms the system as a matter of urgency, a leading doctors’ indemnity organisation has argued at the launch of a new campaign.”
Find article here.

Withdrawing clinically assisted nutrition and hydration (CANH) in patients with prolonged disorders of consciousness: is there still a role for the courts?

Journal of Medical Ethics 2017;43:476-480.
Author: English V, Sheather JC
“Currently, in England and Wales, Court of Protection’s Practice Directive 9E (PD9E) requires all cases of proposed withdrawal or withholding of life-sustaining treatment in relation to adults in a permanent vegetative state (PVS) or minimally conscious state be referred to the Court. This paper looks at the origins of PD9E and contrasts the routine requirement to refer cases to court with the complex clinical terrain that comprises those suffering from prolonged disorders of consciousness.”
Find article here (part of a series of articles on this topic)

Evolving State-Based Contraceptive and Abortion Policies

JAMA. 2017; 317(24): 2481-2482
Authors: Divya Mallampati, Melissa A. Simon, Elizabeth Janiak
“This Viewpoint discusses the importance of US state-based contraceptive and abortion policies given renewed focus by the Trump administration on restrictions to federal funding for reproductive services.”
Find article here.

Ten-year ban for steroid-prescribing doctor

Australian Doctor, 27 June 2017
Author: Anthony Scholefield
“A doctor who wrote in his notes “naughty boy wants to get buff by April” when prescribing steroids and stimulants to hundreds of body-builders has been struck off for 10 years.”
Find article here.